Old Web
English
Sign In
Acemap
>
authorDetail
>
Pamela Sarah Cohen
Pamela Sarah Cohen
Medicine
Melanoma
Oncology
Internal medicine
Tolerability
4
Papers
52
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update
2020
Journal for ImmunoTherapy of Cancer
Julie E. Bauman
Howard A. Burris
Jeffrey Melson Clarke
Manish R. Patel
Daniel Cho
Martin Gutierrez
Ricklie Ann Julian
Aaron Scott
Pamela Sarah Cohen
Joshua Frederick
Céline Robert-Tissot
Honghong Zhou
Kinjal Mody
Karen N. Keating
Robert S. Meehan
Justin F. Gainor
Show All
Source
Cite
Save
Citations (5)
A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).
2019
Journal of Global Oncology
Howard A. Burris
Manish R. Patel
Daniel C. Cho
Jeffrey Melson Clarke
Martin Gutierrez
Tal Z. Zaks
Joshua Frederick
Kristen Hopson
Kinjal Mody
Alverina Binanti-Berube
Céline Robert-Tissot
Kristen Cowens
Ben Breton
Shan Zhong
Honghong Zhou
Pamela Sarah Cohen
Karen N. Keating
Robert S. Meehan
Justin F. Gainor
Show All
Source
Cite
Save
Citations (5)
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study
2006
British Journal of Cancer
MichaelJ. Millward
Colin M. House
David Bowtell
Lisa E Webster
Ian Olver
MartinE. Gore
Michael Copeman
Kevin W. Lynch
Yap A
Yucai Wang
Pamela Sarah Cohen
John J. Zalcberg
Show All
Source
Cite
Save
Citations (42)
Utilisation de derives de 7h-pyrrolo[2,3-d]pyrimidine dans des maladies a tumeur solide
2002
Howard A. Ball
Pamela Sarah Cohen
Lucy Lee
Christina Portrude Ravera
Show All
Source
Cite
Save
Citations (0)
1